Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis

NCT04638517 is registered in ClinicalTrials.gov with The University of Queensland as lead sponsor.

NCT NCT04638517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04638517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
Lead sponsor
The University of Queensland
Phase
Phase 2
Overall status
Terminated
Start date
September 7, 2021
Completion date
January 16, 2025
Enrollment
29 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

dyskeratosis congenita, pulmonary fibrosis, telomere disease, telomere shortening